HD-OPM Archive
Hashtags

#prevention

32 posts

Ezetimibe beyond statins: fewer events, no mortality gain in trials, registry benefits

Nov 07, 2024 · Gokhan Can ♥ 11 · 💬 22 PCSK9, ezetimibe & newer drugs

Evidence digest on ezetimibe. A meta-analysis of 15 RCTs (123,785 patients) found add-on lipid lowering cut cardiovascular events 19% versus statins alone but did not improve all-cause mortality. Other data show moderate statin plus ezetimibe matches high-intensity statins, and registry studies hint at lower mortality, with strong LDL-target attainment.

2025 ACC statement: inflammation is actionable in CVD, with universal hsCRP screening

Oct 09, 2025 · Gokhan Can ♥ 15 · 💬 13 Inflammation & CRP

Summarises the 2025 ACC Scientific Statement (JACC) concluding the inflammation-ASCVD link is now clinically actionable. It recommends universal hsCRP screening in primary and secondary prevention alongside cholesterol, notes IL-6 and fibrinogen also predict risk, and says CT perivascular fat attenuation is promising but not routine. It contrasts this with a more cautious 2002 CDC/AHA workshop.

JACC review: rapid plaque progression precedes rupture and LDL below 70 mg/dL halts it

Jan 02, 2026 · Gokhan Can ♥ 19 · 💬 5 Plaque, CAC & CT angiography

Summarises a 2019 JACC review arguing plaque progression is a necessary, modifiable step between subclinical atherosclerosis and MI, and that preventive strategy should shift toward imaging and aggressively treating subclinical disease. It reports data from PROSPECT, PARADIGM, GLAGOV and PESA showing progression stops at LDL <70 mg/dL and regression needs lower.

High Lp(a) raises CVD death risk 16% per 50 mg/dL, independent of other risk factors

May 11, 2024 · Louis Nervegna ♥ 5 · 💬 22 Lp(a)

Louis argues Lp(a) alone raises heart disease mortality even in people with no other risk factors. Citing a Current Opinion in Lipidology review, he notes each 50 mg/dL increase corresponds to a hazard ratio of 1.16 for CVD mortality, and works an example: Lp(a) of 250 mg/dL would imply roughly an 80% higher risk, taking a 20% lifetime risk to about 36%. The linear extrapolation is his own illustration.

Statins work as well in women as men: 27-trial CTT meta-analysis of 174,000 participants

Dec 19, 2023 · Louis Nervegna ♥ 5 · 💬 11 Statins

Louis rebuts the claim that statins are less effective in women using the Cholesterol Treatment Trialists' meta-analysis of 27 randomized trials. Per 1 mmol/L LDL reduction, proportional reductions in major vascular events and all-cause mortality were similar in women and men, with no adverse effect on cancer or non-CV mortality. Trials averaged 4.9 years, so longer-term benefit is likely larger.

One zoledronate infusion cut vertebral fractures about 44% over 10 years in women 50-60

Jan 18, 2025 · Gokhan Can ♥ 4 · 💬 9 Hormones, women's & men's health

Gokhan shares the NEJM 10-year randomized trial of infrequent zoledronate in early postmenopausal women (50-60 years) with normal-to-low-normal bone density. Zoledronate roughly halved new morphometric vertebral fractures versus placebo, and he calls it a longevity-type drug like statins or aspirin. The trial concerns bone rather than heart outcomes.

REACT: silent atherosclerosis found in 57% of 16,808 adults, 7-9% of 18-29-year-olds

Sep 26, 2026 · Louis Nervegna ♥ 11 · 💬 2 Plaque, CAC & CT angiography

The NEJM REACT study used carotid and femoral ultrasound plus coronary CT angiography in 16,808 adults aged 18-70 without known disease. Plaque was present in 57% overall, appeared in young adults, and a zero calcium score often missed early non-calcified plaque. Ten-year risk scores detected very little silent disease, so keeping risk factors favorable throughout life is the priority.

Statins cause under 10% of reported muscle pain, analysis of 23 RCTs finds

Jun 29, 2026 · Louis Nervegna ♥ 6 · 💬 2 Statins

Louis shares the Oxford/CTT Lancet analysis of 23 large randomized trials (155,000 people) showing muscle pain is common with or without a statin. Over 90% of muscle pain reported on statins was not caused by the drug, and true statin-related cases occurred mainly in the first year, more with high-intensity dosing.

WOSCOPS 20-year follow-up: 5 years of pravastatin gave lasting mortality and event benefit

Apr 07, 2026 · Gokhan Can ♥ 7 · 💬 1 Statins

Describes the 20-year follow-up of the West of Scotland Coronary Prevention Study: 5 years of pravastatin in middle-aged men with high cholesterol and no prior CHD produced a lasting legacy effect, with reduced all-cause, CV and coronary mortality and fewer heart failure and MI hospitalizations. No excess cancer or non-CV mortality was seen.

Lifestyle and drug therapy have additive benefits, so prevention should combine both

Dec 10, 2025 · Louis Nervegna ♥ 7 Cardiovascular disease: the big picture

Louis quotes a statement arguing that cardiometabolic risk is cumulative and multifactorial, that interventions on different pathways give additive rather than competing benefits, and that lifestyle remains foundational while drugs targeting LDL-driven atherogenesis can add durable effect. He posts it as a counter to influencers who pit the two against each other.